Public Employees Retirement System of Ohio Takes Position in Boston Scientific Corporation $BSX

Public Employees Retirement System of Ohio purchased a new stake in Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, HoldingsChannel.com reports. The firm purchased 571,485 shares of the medical equipment provider’s stock, valued at approximately $24,391,000.

Other large investors also recently added to or reduced their stakes in the company. Renaissance Group LLC bought a new stake in Boston Scientific in the fourth quarter valued at approximately $28,064,000. Perigon Wealth Management LLC acquired a new position in Boston Scientific in the second quarter valued at about $883,000. Y Intercept Hong Kong Ltd increased its holdings in shares of Boston Scientific by 148.8% in the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after acquiring an additional 670,060 shares in the last quarter. Wealthfront Advisers LLC acquired a new stake in shares of Boston Scientific during the second quarter worth about $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab lifted its holdings in shares of Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after purchasing an additional 28,961 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BSX has been the subject of several research analyst reports. Weiss Ratings lowered Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Robert W. Baird set a $56.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Citigroup cut their price objective on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Barclays reduced their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. Finally, TD Cowen restated a “buy” rating and issued a $56.00 price target on shares of Boston Scientific in a report on Tuesday. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Price Performance

NYSE:BSX opened at $46.82 on Friday. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a market cap of $67.85 billion, a P/E ratio of 18.96, a P/E/G ratio of 1.02 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The stock’s 50-day simple moving average is $46.56 and its 200 day simple moving average is $56.65.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has approved a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Insider Activity

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger bought 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.